Fosphenytoin

Drug Profile

Fosphenytoin

Alternative Names: ACC 9653; ACC 9653-010; Cerebyx; Cereneu; Fosphenytoin sodium hydrate; Fostoin; NPC-06; PD 135711-15B; Pro-Epanutin; Prodilantin; Prophenytoin

Latest Information Update: 17 Jan 2012

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Nobelpharma; Pfizer
  • Class Antiepileptic drugs; Hydantoins; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Stroke

Most Recent Events

  • 17 Jan 2012 Launched for Epilepsy in Japan (IV)
  • 01 Jul 2011 Registered for Epilepsy in Japan (IV)
  • 30 Jun 2010 Preregistration for Epilepsy in Japan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top